Anesiva Announces Second Quarter 2008 Financial Results ...( This press release includes forward...)

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward- looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: whether Zingo gains FDA approval in the adult indication, the degree to which Zingo gains market acceptance, and whether the Adlea clinical trials will be successful. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's annual report on Form 10-K for the year ended December 31, 2007, and its most recent filing on Form 10-Q.

Anesiva, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

For the three months For the six months

ended June 30, ended June 30,

2008 2007 2008 2007

Contract revenues $302 $- $303 $-

Operating expenses:

Manufacturing start-up costs 1,125 - 1,125 -

Research and development 13,063 8,412 26,447 15,374

Sales, general and

admini
'/>"/>